NASDAQ:PALI Palisade Bio (PALI) Stock Price, News & Analysis $0.60 +0.02 (+2.75%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.60 +0.00 (+0.17%) As of 09/12/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Palisade Bio Stock (NASDAQ:PALI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Palisade Bio alerts:Sign Up Key Stats Today's Range$0.57▼$0.6050-Day Range$0.54▼$1.2452-Week Range$0.53▼$4.32Volume192,968 shsAverage Volume533,810 shsMarket Capitalization$5.45 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingBuy Company Overview Palisade Bio, Inc. is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity. The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors. Palisade Bio is also advancing a pipeline of next‐generation candidates designed to support combination approaches with checkpoint inhibitors, adoptive cell therapies and other standard‐of‐care modalities. The platform’s modular design enables the development of both injectable and implantable formats to address a variety of tumor types and anatomic locations. Palisade Bio operates out of facilities in the United States and collaborates with academic research centers, contract research organizations and biotechnology partners to accelerate its clinical programs. The company maintains a management team with extensive experience in oncology drug development, immunology and precision medicine. As it progresses through clinical milestones, Palisade Bio aims to validate its platform’s capacity to enhance anti‐tumor efficacy while reducing systemic immune‐related adverse events.AI Generated. May Contain Errors. Read More Palisade Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScorePALI MarketRank™: Palisade Bio scored higher than 62% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPalisade Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Upside PotentialPalisade Bio has a consensus price target of $12.00, representing about 1,906.7% upside from its current price of $0.60.Amount of Analyst CoveragePalisade Bio has received no research coverage in the past 90 days.Read more about Palisade Bio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Palisade Bio are expected to grow in the coming year, from ($12.43) to ($2.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Palisade Bio is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Palisade Bio is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPalisade Bio has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Palisade Bio's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.70% of the float of Palisade Bio has been sold short.Short Interest Ratio / Days to CoverPalisade Bio has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Palisade Bio has recently decreased by 21.04%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPalisade Bio does not currently pay a dividend.Dividend GrowthPalisade Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.70% of the float of Palisade Bio has been sold short.Short Interest Ratio / Days to CoverPalisade Bio has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Palisade Bio has recently decreased by 21.04%, indicating that investor sentiment is improving significantly. News and Social Media3.0 / 5News Sentiment0.44 News SentimentPalisade Bio has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Palisade Bio this week, compared to 1 article on an average week.Search Interest10 people have searched for PALI on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows2 people have added Palisade Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Palisade Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.65% of the stock of Palisade Bio is held by insiders.Percentage Held by InstitutionsOnly 11.79% of the stock of Palisade Bio is held by institutions.Read more about Palisade Bio's insider trading history. Receive PALI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Palisade Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PALI Stock News HeadlinesHealth Canada clears Palisade Bio’s trial of Crohn’s disease treatmentSeptember 8, 2025 | finance.yahoo.comPalisade Bio receives Health Canada clearance for Phase 1b PALI-2108 trialSeptember 6, 2025 | msn.comReagan’s former tech advisor sharing bombshell announcementGeorge Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert. He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves. | Banyan Hill Publishing (Ad)Palisade Bio receives Health Canada clearance for Phase 1b PALI-2108 trialSeptember 6, 2025 | msn.comPalisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn’s Disease (FSCD)September 6, 2025 | markets.businessinsider.comPalisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn’s Disease (FSCD)September 6, 2025 | markets.businessinsider.comPalisade Bio Advances PALI-2108 as First Dual-Acting Therapy for Fibrostenotic Crohn's Disease, Dosing to Begin H2 2025September 5, 2025 | quiverquant.comQPalisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD)September 5, 2025 | globenewswire.comSee More Headlines PALI Stock Analysis - Frequently Asked Questions How have PALI shares performed this year? Palisade Bio's stock was trading at $1.65 on January 1st, 2025. Since then, PALI stock has decreased by 63.8% and is now trading at $0.5980. How were Palisade Bio's earnings last quarter? Palisade Bio, Inc. (NASDAQ:PALI) posted its quarterly earnings data on Monday, August, 11th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $0.10. When did Palisade Bio's stock split? Palisade Bio's stock reverse split on the morning of Monday, April 8th 2024.The 1-15 reverse split was announced on Monday, April 8th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Palisade Bio? Shares of PALI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Palisade Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Palisade Bio investors own include Onconova Therapeutics (ONTX), Sesen Bio (SESN), Iterum Therapeutics (ITRM), Oncobiologics (OTLK), Bionano Genomics (BNGO), PayPal (PYPL) and Tesla (TSLA). Company Calendar Last Earnings8/11/2025Today9/13/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PALI CIK1357459 Webwww.palisadebio.com Phone(858) 704-4900FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Price Target for Palisade Bio$12.00 High Price Target$16.00 Low Price Target$8.00 Potential Upside/Downside+1,906.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($4.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.44 million Net MarginsN/A Pretax MarginN/A Return on Equity-214.94% Return on Assets-135.09% Debt Debt-to-Equity RatioN/A Current Ratio1.62 Quick Ratio1.62 Sales & Book Value Annual Sales$250 thousand Price / Sales21.82 Cash FlowN/A Price / Cash FlowN/A Book Value$2.71 per share Price / Book0.22Miscellaneous Outstanding Shares9,120,000Free Float9,060,000Market Cap$5.45 million OptionableNot Optionable Beta1.40 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:PALI) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredApple’s falling behindApple just posted record-breaking results, yet its stock barely moved — because in today’s market, investors o...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palisade Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palisade Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.